Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 892 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Condition Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Testing Ultra-processed Warning Labels and Not-Ultra-processed Labels in United States

NCT07863570
View directory record Official record
Conditions
Ultra-processed Labels
Interventions
NIB: Label exposure in mock-up UPF and Not-UPF products, NIB+UPFWL: Label exposure in mock-up UPF and Not-UPF products, NIB+Not-UPF Black: Label exposure in mock-up UPF and Not-UPF products, NIB+Not-UPF Green: Label exposure in mock-up UPF and Not-UPF products
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
12,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Development of Education Materials for Prevention of FAS in Russia

NCT01971398
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome (FAS), Alcohol Related Neurodevelopmental Disorder, Alcohol Use Complicating Pregnancy, Unspecified Trimester
Interventions
Positive FASD education brochure, Negative FASD education brochure, Active comparator (a general women's health brochure)
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women

NCT06646692
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Anxiety, Depression - Major Depressive Disorder
Interventions
Mindful Self Compassion, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

NCT01328444
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 29, 2026, 6:32 PM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

NCT04944992
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional

Building Healthy Eating and Self-Esteem Together for University Students

NCT07060534
View directory record Official record
Conditions
Eating Disorders (Excluding Anorexia Nervosa), Binge-Eating Disorder
Interventions
Building Healthy Eating and Self-Esteem Together for University Students, Present-Centered Therapy
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

NCT03748134
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
Biological · Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Anaheim, California • Orange, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Results available

Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease

NCT00646204
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Memantine, placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 29, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
View directory record Official record
Conditions
COVID-19
Interventions
Sotrovimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Days to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Cullman, Alabama • Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting No phase listed Observational

Left Atrial Strain and Cryptogenic Stroke

NCT07224178
View directory record Official record
Conditions
Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source, Recurrent Ischemic Stroke
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Mood Internet Intervention Research Project

NCT01358487
View directory record Official record
Conditions
Major Depression
Interventions
Online self-help course plus live follow-up if needed, Online + incentives Follow-up Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

NCT02496884
View directory record Official record
Conditions
Fibromyalgia
Interventions
DS-5565, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NCT03113760
View directory record Official record
Conditions
NLRC4-MAS, XIAP Deficiency
Interventions
Tadekinig alfa, 0.9% sodium chloride
Drug · Other
Lead sponsor
AB2 Bio Ltd.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 29, 2026, 6:32 PM EDT
Not yet recruiting Not applicable Interventional

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)

NCT06470035
View directory record Official record
Conditions
Major Depressive Disorder \(MDD, Depressive Disorder, Major
Interventions
Active VeNS Device, Sham VeNS Device
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Assistive Technology and Reduced Caregiver Burden

NCT05352529
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life, Activities of Daily Living
Interventions
The MapHabit system, Dementia educational videos
Device
Lead sponsor
MapHabit, Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

NCT03047629
View directory record Official record
Conditions
Parkinson's Disease, Constipation
Interventions
ENT-01, Placebo
Drug · Other
Lead sponsor
Enterin Inc.
Industry
Eligibility
30 Years to 86 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
16
States / cities
Palm Spring, California • Redding, California • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 29, 2026, 6:32 PM EDT